University of Florida records tie glucosamine to a 25% higher chance of MCI turning into dementia

A 25% increase is a relative figure. What it means for a patient depends on how often MCI progressed to dementia in people who did not take glucosamine. According to the UF Health release, the result held after adjustment for age, sex and demographics, but the release does not give that baseline rate or say whether the 25% comes from an odds ratio or a hazard ratio ^[1]. Without the baseline, the finding cannot be turned into a personal risk for anyone taking the supplement.

The group sizes need the same care. The release says 8% of both groups reported glucosamine use, and that this "included 1,896 people with ADRD and 2,750 people with MCI" ^[3]. That wording leaves open whether those are the users or the whole groups. If they are the users, the MCI cohort would be about 34,000 people and the dementia cohort about 23,700 ^[16].

Then there is the control. The adjustments the release lists are age, sex and demographics ^[1]. Glucosamine is sold without a prescription and is especially popular with older adults who take it for joint discomfort ^[15]. So users differ from non-users in at least one way those variables do not describe. The release makes the general point itself: other differences between people who take a supplement and those who do not may contribute to the results ^[13]. "While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention," said Matt Gentry, a co-author who chairs UF's Department of Biochemistry and Molecular Biology ^[11].

The mortality result allows two readings. The link appeared in dementia patients and not in the MCI group ^[5], and the release interprets that as a sign glucosamine may have a stronger effect once dementia is established ^[17]. A confounder that matters more in sicker patients could produce the same split.

The lab work is the reason to take the records seriously. Attaching sugar structures to proteins is a normal part of cell biology ^[7]. The team found signs that the process runs to excess in Alzheimer's disease, and its experiments suggest glucosamine may push it further ^[7]. Those experiments were done in human brain tissue and in mouse models ^[6]. The thing this doesn't tell you is whether a person taking a joint-supplement dose for years gets enough into the brain to matter.

Ramon Sun, the senior author and director of UF's Center for Advanced Spatial Biomolecule Research, framed the stakes in terms of scale, citing about 7 million people in the United States living with Alzheimer's ^[10]. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse," he said ^[9].